ArticleCell metabolism2018
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway.
Open access · bronzeAbstract read
In one paragraph
Article in Cell metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- European Association for the Study of Obesity (EASO) Position Statement on Medical Nutrition Therapy for the Management of Individuals with Overweight or Obesity and Cancer.Obesity facts · 2025Guideline
- HER2-driven mammary tumorigenesis enhances bioenergetics despite reductions in mitochondrial content.eLife · 2026Article
- Article
- Streptococcus gallolyticus supernatant induces M2 macrophage polarization and activates IL-17 F signaling in colorectal tumorigenesis.Gut pathogens · 2025Article
- Structural basis for substrate binding, catalysis, and inhibition of cancer target mitochondrial creatine kinase by a covalent inhibitor.Structure (London, England : 1993) · 2025Article
- CKMT1B regulates the proliferation, migration, invasion, and apoptosis of colorectal cancer cells through the AKT/mTOR/STAT3 pathway.Molecular genetics and genomics : MGG · 2025Article
- CKMT1 deficiency contributes to mitochondrial dysfunction and promotes intestinal epithelial cell apoptosis via reverse electron transfer-derived ROS in colitis.Cell death & disease · 2025Article
- MTHFD2 promotes osteoclastogenesis and bone loss in rheumatoid arthritis by enhancing CKMT1-mediated oxidative phosphorylation.BMC medicine · 2025Article
- It Is Not Just About Storing Energy: The Multifaceted Role of Creatine Metabolism on Cancer Biology and Immunology.International journal of molecular sciences · 2024Review
- Hydrogel models of pancreatic adenocarcinoma to study cell mechanosensing.Biophysical reviews · 2024Review
- A covalent creatine kinase inhibitor ablates glioblastoma migration and sensitizes tumors to oxidative stress.Scientific reports · 2024Article
- CKB Promotes Mitochondrial ATP Production by Suppressing Permeability Transition Pore.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Context-dependent roles for ubiquitous mitochondrial creatine kinase CKMT1 in breast cancer progression.Cell reports · 2024Article
- Prognostic value of mitochondrial CKMT2 in Pan-cancer and its tumor immune correlation analysis.Scientific reports · 2024Article
- Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth.Cell metabolism · 2024Article
- Breast cancers as ecosystems: a metabolic perspective.Cellular and molecular life sciences : CMLS · 2023Review
- Creatine kinase brain-type regulates BCAR1 phosphorylation to facilitate DNA damage repair.iScience · 2023Article
- Role of creatine shuttle in colorectal cancer cells.Oncotarget · 2023Article
- A Zeb1/MtCK1 metabolic axis controls osteoclast activation and skeletal remodeling.The EMBO journal · 2023Article
- Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients.Journal of translational medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 4 institutions in 1 country.
Kiran KurmiMolecular Pharmacology and Experimental Therapeutics Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN 55905, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Sadae HitosugiDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Jia YuDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Felix Boakye-AgyemanDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Elizabeth K WieseMolecular Pharmacology and Experimental Therapeutics Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN 55905, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Thomas R LarsonMolecular Pharmacology and Experimental Therapeutics Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN 55905, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Qing DaiDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Yuichi J MachidaDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Zhenkun LouDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Liewei WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Judy C BougheyDepartment of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Scott H KaufmannDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Matthew P GoetzDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Larry M KarnitzDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Taro HitosugiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: hitosugi.taro@mayo.edu.
Mayo Clinic · USWinnMed · USMayo Clinic in Arizona · USUniversity of Chicago · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MThe Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9MPredoctoral Training Program in Molecular PharmacologyT32GM072474 · NIGMS · MAYO CLINIC ROCHESTER · PI KARNITZ, LARRY M · 2005 to 2020
$2.4MRole of CPT1A as a lysine succinyltransferase in tumorigenesisR01CA225680 · NCI · MAYO CLINIC ROCHESTER · PI HITOSUGI, TARO · 2018 to 2022
$1.8MInvestigate the role of TPD52-AMPK pathway in tumorigenesis and cancer therapyR01CA196648 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2016 to 2020
$1.7MNCI NIH HHS N01 CA015083NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA196648NCI NIH HHS R01 CA225680NIGMS NIH HHS T32 GM072474
Abstract
How mitochondrial metabolism is altered by oncogenic tyrosine kinases to promote tumor growth is incompletely understood. Here, we show that oncogenic HER2 tyrosine kinase signaling induces phosphorylation of mitochondrial creatine kinase 1 (MtCK1) on tyrosine 153 (Y153) in an ABL-dependent manner in breast cancer cells. Y153 phosphorylation, which is commonly upregulated in HER2
Indexed as
Drug Resistance, NeoplasmEnergy MetabolismAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCell Line, TumorCell Transformation, NeoplasticCreatine KinaseCreatinineEnergy TransferErb-b2 Receptor Tyrosine KinasesFemaleGene Knockdown TechniquesHumansLapatinibAntineoplastic AgentsCKMT1A protein, humanCreatine KinaseCreatininecyclocreatineERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLapatinibMitochondrial ProteinsPhosphocreatineTrastuzumabABL kinasebreast cancercyclocreatineHER2 tyrosine kinasemitochondriamitochondrial bioenergeticsmitochondrial creatine kinaseoncogenic tyrosine kinasephosphocreatinetyrosine phosphorylation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.